Adjuvant Therapy for Stage I and II Non-Small Cell Lung Cancer

Evan C Naylor

doi:10.1016/j.soc.2016.03.003

Adjuvant Therapy for Stage I and II Non-Small Cell Lung Cancer

Surg Oncol Clin N Am. 2016 Jul;25(3):585-99. doi: 10.1016/j.soc.2016.03.003.

Author

Evan C Naylor¹

Affiliation

¹ Hematology and Oncology, Meridian Cancer Care, Southern Ocean Medical Center, 1140 Route 72 West, Manahawkin, NJ 08050, USA. Electronic address: enaylor@meridianhealth.com.

PMID: 27261917
DOI: 10.1016/j.soc.2016.03.003

Abstract

Patients with stage I and stage II non-small cell lung cancer undergoing complete resection have a 40% to 70% 5-year overall survival despite optimal local therapy. Chemotherapy administered after complete resection has been shown to improve overall survival at 5 years by approximately 5%. This improvement in survival may be confined to patients with stage IB disease 4 cm or greater, and to those with hilar or mediastinal lymph node involvement. The optimal chemotherapy regimen appears to be cisplatin-based doublet or triplet chemotherapy for 3 to 4 cycles. The addition of biologic agents has failed to improve outcomes.

Keywords: Adjuvant; Chemotherapy; Non–small cell lung cancer.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / surgery
Chemotherapy, Adjuvant
Cisplatin / therapeutic use
Combined Modality Therapy
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / surgery
Neoplasm Staging
Treatment Outcome

Substances

Cisplatin